Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : NASI (North American Scientific, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: TJL who wrote (479)	3/20/1998 9:59:00 AM
From: Jeffrey Beckman	Respond to of 658

Yeah, but you are saying that NASI will kill their estimates, without raising the likelihood that THRX will as well. Anyway, no use squabbling intrasector. Jeff (long THRX, NASI, INIS)

To: TJL who wrote (479)	3/20/1998 10:50:00 AM
From: BDR	Read Replies (1) \| Respond to of 658

<<NASI is only trading at a forward pe of 42, and 21 for 99.>> It sounds like NASI is fairly priced now through the rest of 1998 and even into 99. Growth will slow at some point. By the way, the number of newly diagnosed prostate cancer cases has leveled off and may actually be declining.

To: TJL who wrote (479)	3/21/1998 2:13:00 AM
From: Michael Paul Langley	Read Replies (1) \| Respond to of 658

NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--March 17, 1998--North American Scientific Inc. (Nasdaq:NASI) Tuesday announced that net sales for the first quarter, ended Jan. 31, 1998, decreased 2 percent to approximately $820,000, compared with $839,000 for the comparable 1997 period. Net income decreased to $42,000, or 1 cent per share, from net income of $77,000, or 3 cents per share, in the same fiscal 1997 period. President and Chief Executive Officer L. Michael Cutrer said: "We began to generate revenue from our new I-125 brachytherapy line in January, the last month of the quarter. First-quarter expenses were increased by significant R&D and other start-up costs associated with the brachytherapy line, as well as waste disposal costs associated with several years of operation." Cutrer concluded: "Manufacturing capacity associated with our new I-125 brachytherapy line continues to increase, and we anticipate that sales in this sector will be a significant part of our second-quarter sales numbers." North American Scientific manufactures and markets a broad line of low-level radioactive sources and standards for medical therapeutic, scientific and industrial uses.

To: TJL who wrote (479)	4/4/1998 1:03:00 PM
From: richard houchin	Read Replies (1) \| Respond to of 658

Nasi Investors: It was great meeting the TLJ brothers, thanks i really enjoyed meeting you guys. TLJ took notes at the meeting and said he would recap the significant items relative nasi as soon as he gets back home. I was very impressed with the furture of nasi. My prediction in two years (discounting cure for prostate cancer or stock splits) nasi will be $100 per shaare. Remember, i'm very biased; therefore, read TLJ's recap of the meeting before you make your own judgement on nasi. Hopefully, we should hear from TLJ this coming week. thanks, richard ps: TLJ: don't forget clv